Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy

Human Pathology

Volumn 39, Issue 6, 2008, Pages 837-845

  Larbcharoensub, Noppadol ^a   Leopairat, Juvady ^a   Sirachainan, Ekaphop ^b   Narkwong, Ladawan ^b   Bhongmakapat, Thongchai ^a   Rasmeepaisarn, Kawin ^c   Janvilisri, Tavan ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

ABC transporter; Multidrug resistance; Multidrug resistance associated protein 1; Nasopharyngeal carcinoma; Prognostic factor

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SURVIVAL TIME; TREATMENT FAILURE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM STAGING; P-GLYCOPROTEIN; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 44649142102     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.10.009     Document Type: Article

References (33)

1. Chan A.T., Teo P.M., and Johnson P.J. Nasopharyngeal carcinoma. Ann Oncol 13 (2002) 1007-1015
2. Fandi A., Altun M., Azli N., Armand J.P., and Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 21 (1994) 382-397
3. Teo P.M., Kwan W.H., Lee W.Y., Leung S.F., and Johnson P.J. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 77 (1996) 2423-2431
4. Sanguineti G., and Corvo R. Treatment of nasopharyngeal carcinoma: state of the art and new perspectives (review). Oncol Rep 6 (1999) 377-391
5. Al Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
6. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., and Wang W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21 (2003) 631-637
7. Ma B.B., and Chan A.T. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 103 (2005) 22-31
8. Yuen A.R., and Sikic B.I. Multidrug resistance in lymphomas. J Clin Oncol 12 (1994) 2453-2459
9. Kaye S.B. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 10 (1998) S15-S19
10. Moureau-Zabotto L., Ricci S., Lefranc J.P., et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94 (2006) 473-480
11. Mahadevan D., and Shirahatti N. Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr Cancer Drug Targets 5 (2005) 445-455
12. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39 (1999) 361-398
13. Ieiri I., Takane H., and Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 43 (2004) 553-576
14. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5 (2004) 21-53
15. Kruh G.D., Zeng H., Rea P.A., et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 33 (2001) 493-501
16. Ohno N., Tani A., Chen Z.S., et al. Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res 7 (2001) 3120-3126
17. Pajic M., Norris M.D., Cohn S.L., and Haber M. The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. Cancer Lett 228 (2005) 241-246
18. Filipits M., Pohl G., Rudas M., et al. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 23 (2005) 1161-1168
19. Doyle L.A., Yang W., Abruzzo L.V., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95 (1998) 15665-15670
20. Doyle L.A., and Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 (2003) 7340-7358
21. Janvilisri T., Shahi S., Venter H., Balakrishnan L., and van Veen H.W. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J 385 (2005) 419-426
22. Sargent J.M., Williamson C.J., Maliepaard M., Elgie A.W., Scheper R.J., and Taylor C.G. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115 (2001) 257-262
23. Yoh K., Ishii G., Yokose T., et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10 (2004) 1691-1697
24. Diestra J.E., Scheffer G.L., Catala I., et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198 (2002) 213-219
25. Meaden E.R., Hoggard P.G., Maher B., Khoo S.H., and Back D.J. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 17 (2001) 1329-1332
26. Scheffer G.L., Kool M., Heijn M., et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60 (2000) 5269-5277
27. Baujat B., Audry H., Bourhis J., et al. Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev 4 (2006) CD004329
28. Maliepaard M., Scheffer G.L., Faneyte I.F., et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61 (2001) 3458-3464
29. Rajagopal A., and Simon S.M. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 14 (2003) 3389-3399
30. Hipfner D.R., Deeley R.G., and Cole S.P. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461 (1999) 359-376
31. Gupta N., Martin P.M., Miyauchi S., et al. Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun 343 (2006) 571-577
32. Ohsawa M., Ikura Y., Fukushima H., et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 68 (2005) 422-431
33. Sharp S.Y., Smith V., Hobbs S., and Kelland L.R. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br J Cancer 78 (1998) 175-180